采用ELISA检测人血浆SC5b-9方法的建立及对SLE的临床意义

ELISA for Detection of SC5b-9 Levels in Plasma and Its Clinical Significance in SLE Disease

补体系统活化C_5～C_9形成末端补体复合物(terminal complement complex,TCC),其中结合在细胞膜上的称为膜攻击复合物(membrane attack complex,MAC),存在于血浆中的为SC_5b-9。SC_5b-9、MAC及人工制备的多聚C_9(poly C_9)均形成单个补体中所没有的新抗原,用兔抗人MACIgG可与SC_5b-9、poly C_9有特异反应。本组曾报道了TCC研究中兔抗人MAC抗体的制备纯化,SC_5b-9的纯化。在上述工作基础上用纯化的抗MAC IgG和辣根过氧化物酶联抗MAC IgG为双抗体,中间夹纯化抗原SC_5b-9或血浆,设计建立了双抗体夹心ELISA法,并初步检测了一些正常人和SLE患者血浆中SC_5b-9的浓度,发现活动期SLE患者血浆中SC_5b-9浓度明显高于非活动期SLE患者和正常人。

Using IgG from rabbit antiserum to human MAC neoantigens and SC5b-9, we established a sandwich ELISA for detecting SC5b-9 levels in human plasma. SC5b-9 was measured in 51 normal plasma samples and 40 plasma samples from patients with SLE.We found that SC5b-9 levels in 96.1% of the controls and in 78.9% of the patients with inactive SLE were below 450 ng/ml, while SC5b-9 levels in 81.0% of the patients with active SLE were above 450ng/ml.This Shows that SC5b-9 levels may be useful for diagnosing patients with clinically active SLE.